Post-earnings recap
Reported
Thu, May 8, 2025
EPS actual
$-1.04
EPS est.
$-0.99
EPS surprise
-5.05%
1-day move
+4.17%
Est. EPS
—
Est. Rev
—
Impl. Move
—
Crinetics Pharmaceuticals reported a wider-than-expected loss per share, which may raise concerns among investors. However, the stock rose by 4.17%, likely due to positive sentiment around their ongoing development efforts. Investors may be encouraged by management's focus on future growth despite the EPS miss.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.04 | N/A | -5.05% |
| Revenue | N/A | N/A | N/A |
Management remains focused on advancing their product pipeline. They acknowledged the EPS miss but emphasized long-term growth prospects.
Management highlighted ongoing development efforts and future potential.
They expressed confidence in their pipeline despite the EPS miss.